Blueline Drug Target Program
The Blueline Drug Target Program offers a unique opportunity for academic researchers with novel targets and mechanisms of action to collaborate with Blueline to translate their research discoveries into high impact therapeutics. Blueline Bioscience’s experienced team of drug discovery experts, biotechnology entrepreneurs and life science investment professionals will collaborate with funded teams to advise on the design of a research plan to rigorously evaluate the therapeutic potential of novel targets.
The objectives of the Blueline Drug Target program are:
- To advance the validation of novel drug targets and/or lead compounds;
- To forge collaborations between leading academic researchers, biotechnology entrepreneurs, and life science investors;
- To identify academic projects with very high potential to address unmet medical needs and to be first-in-class in key therapeutic fields; and
- To ultimately create biotech companies to progress these discoveries toward commercialization.
Blueline Bioscience financial contributions for this Program are subject to availability of funds. Funds will be administered through a Sponsored Research Agreement negotiated between Blueline Bioscience and the Host Institution of the Principal Investigator.
- The maximum amount per grant is $150,000 for up to one year, non-renewable.
- It is anticipated that up to 10 grants will be funded.
Eligible Research Areas
The eligible research areas for this Program are limited to the fields of:
- Neurodegenerative diseases
- Orphan diseases
- Regenerative medicine
Successful applicants must provide convincing rationale for the therapeutic role of the target or mechanism, the potential for therapeutic impact, and the distinctive capabilities and insights of their research team to achieve validation.
- Novelty of the target and a compelling rationale for validation and further development;
- The unique capabilities and insights of the applicants to pursue validation of the proposed target;
- The potential for clinical impact on the disease of interest;
- The ability to generate meaningful target validation within the one year granting period;
- The qualifications and track record of the applicants; and
- An awareness of and ability to be competitive with other academic or industry groups working in the specific area.
How to Apply
This program has a two-step application process:
Phase 1: Submit a one-page Letter of Registration in PDF to email@example.com, deadline at 11 pm ET on August 29th, 2014. These letters will be screened for relevance to the CFP.
The Letter of Registration is a one page summary of your proposal (Ariel size 11, single-spaced, 2.54 margins unless otherwise noted) and should include:
- The name of the Principal Applicant and additional team members (maximum of three total), including host institutions;
- The project title;
- The name of the Institution that will administer the funds for the project; and
- A brief summary of hte proposed research, indicating the research area and potential target(s) to be studied
Phase 2: Applicants successful in Phase 1 will be invited to download the submit a Full Proposal by 11 pm ET on October 10th, 2014. To download the Full Proposal form, please CLICK HERE.
For additional details and a full description of the application process CLICK HERE.
Inquiries can be directed to firstname.lastname@example.org. Please note that while we are happy to answer technical questions related to the application process, we are not able to provide feedback or advice on application development.